Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1241

1.

Does MRI trump pathology? A new era for staging and monitoring of kidney fibrosis.

Caroli A, Remuzzi A, Remuzzi G.

Kidney Int. 2019 Oct 25. pii: S0085-2538(19)31033-6. doi: 10.1016/j.kint.2019.10.008. [Epub ahead of print] No abstract available.

PMID:
31902648
2.

Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration.

Casiraghi F, Perico N, Gotti E, Todeschini M, Mister M, Cortinovis M, Portalupi V, Plati AR, Gaspari F, Villa A, Introna M, Longhi E, Remuzzi G.

Stem Cells Transl Med. 2019 Dec 24. doi: 10.1002/sctm.19-0185. [Epub ahead of print]

3.

Update on mesenchymal stromal cell studies in organ transplant recipients.

Fiori S, Remuzzi G, Casiraghi F.

Curr Opin Organ Transplant. 2020 Feb;25(1):27-34. doi: 10.1097/MOT.0000000000000716.

PMID:
31815791
4.

More about Factor H Autoantibodies in Membranous Nephropathy.

Valoti E, Noris M, Remuzzi G.

N Engl J Med. 2019 Oct 17;381(16):1590-1592. doi: 10.1056/NEJMc1905608. No abstract available.

PMID:
31618548
5.

Reply to 'Strengths and limitations of estimated and measured GFR'.

Porrini E, Ruggenenti P, Luis-Lima S, Carrara F, Jiménez A, de Vries APJ, Torres A, Gaspari F, Remuzzi G.

Nat Rev Nephrol. 2019 Dec;15(12):785-786. doi: 10.1038/s41581-019-0214-8. No abstract available.

PMID:
31578496
6.

Rationale and population-based prospective cohort protocol for the disadvantaged populations at risk of decline in eGFR (CO-DEGREE).

Gonzalez-Quiroz M, Nitsch D, Hamilton S, O'Callaghan Gordo C, Saran R, Glaser J, Correa-Rotter R, Jakobsson K, Singh A, Gunawardena N, Levin A, Remuzzi G, Caplin B, Pearce N; DEGREE Study Steering Committee.

BMJ Open. 2019 Sep 24;9(9):e031169. doi: 10.1136/bmjopen-2019-031169.

7.

Autotaxin Inhibitor Protects from Chronic Allograft Injury in Rat Kidney Allotransplantation.

Cortinovis M, Aiello S, Mister M, Conde-Knape K, Noris M, Novelli R, Solini S, Rodriguez Ordonez PY, Benigni A, Remuzzi G.

Nephron. 2020;144(1):38-48. doi: 10.1159/000502908. Epub 2019 Sep 24.

PMID:
31550726
8.

Alteration of thyroid hormone signaling triggers the diabetes-induced pathological growth, remodeling, and dedifferentiation of podocytes.

Benedetti V, Lavecchia AM, Locatelli M, Brizi V, Corna D, Todeschini M, Novelli R, Benigni A, Zoja C, Remuzzi G, Xinaris C.

JCI Insight. 2019 Sep 19;4(18). pii: 130249. doi: 10.1172/jci.insight.130249.

9.

Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes.

Valoti E, Noris M, Perna A, Rurali E, Gherardi G, Breno M, Parvanova Ilieva A, Petrov Iliev I, Bossi A, Trevisan R, Dodesini AR, Ferrari S, Stucchi N, Benigni A, Remuzzi G, Ruggenenti P.

Front Genet. 2019 Jul 26;10:681. doi: 10.3389/fgene.2019.00681. eCollection 2019.

10.

Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab.

Podestà MA, Gennarini A, Portalupi V, Rota S, Alessio MG, Remuzzi G, Ruggenenti P.

Nephron. 2020;144(1):30-35. doi: 10.1159/000501858. Epub 2019 Jul 23.

PMID:
31336376
11.

Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy.

Cassis P, Locatelli M, Corna D, Villa S, Rottoli D, Cerullo D, Abbate M, Remuzzi G, Benigni A, Zoja C.

Kidney Int. 2019 Oct;96(4):906-917. doi: 10.1016/j.kint.2019.04.024. Epub 2019 May 10.

PMID:
31307778
12.

Sirt3 Deficiency Shortens Life Span and Impairs Cardiac Mitochondrial Function Rescued by Opa1 Gene Transfer.

Benigni A, Cassis P, Conti S, Perico L, Corna D, Cerullo D, Zentilin L, Zoja C, Perna A, Lionetti V, Giacca M, Trionfini P, Tomasoni S, Remuzzi G.

Antioxid Redox Signal. 2019 Dec;31(17):1255-1271. doi: 10.1089/ars.2018.7703. Epub 2019 Aug 2.

PMID:
31269804
13.

A First Step toward a New Approach to Treating Membranous Nephropathy.

Ruggenenti P, Remuzzi G.

N Engl J Med. 2019 Jul 4;381(1):86-88. doi: 10.1056/NEJMe1906666. No abstract available.

PMID:
31269372
14.

Mesenchymal Stromal Cells for Transplant Tolerance.

Podestà MA, Remuzzi G, Casiraghi F.

Front Immunol. 2019 Jun 4;10:1287. doi: 10.3389/fimmu.2019.01287. eCollection 2019. Review.

15.

Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both?

Noris M, Remuzzi G.

Kidney Int. 2019 Jul;96(1):13-15. doi: 10.1016/j.kint.2019.02.038.

PMID:
31229026
16.

A preclinical overview of emerging therapeutic targets for glomerular diseases.

Cassis P, Zoja C, Perico L, Remuzzi G.

Expert Opin Ther Targets. 2019 Jul;23(7):593-606. doi: 10.1080/14728222.2019.1626827. Epub 2019 Jun 12.

PMID:
31150308
17.

Engineering the vasculature of decellularized rat kidney scaffolds using human induced pluripotent stem cell-derived endothelial cells.

Ciampi O, Bonandrini B, Derosas M, Conti S, Rizzo P, Benedetti V, Figliuzzi M, Remuzzi A, Benigni A, Remuzzi G, Tomasoni S.

Sci Rep. 2019 May 29;9(1):8001. doi: 10.1038/s41598-019-44393-y.

18.

[Drugs for rare diseases: the blessing of being orphans.]

Costa E, Schieppati A, Luzzatto L, Remuzzi G.

Recenti Prog Med. 2019 May;110(5):221-229. doi: 10.1701/3163.31444. Italian.

PMID:
31140454
19.

Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS.

Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M, Cremaschi A, Bresin E, Donadelli R, Alizzi S, Amoroso A, Benigni A, Remuzzi G, Noris M.

Front Immunol. 2019 May 1;10:853. doi: 10.3389/fimmu.2019.00853. eCollection 2019.

20.

Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.

Ruggiero B, Trillini M, Tartaglione L, Rotondi S, Perticucci E, Tripepi R, Aparicio C, Lecchi V, Perna A, Peraro F, Villa D, Ferrari S, Cannata A, Mazzaferro S, Mallamaci F, Zoccali C, Bellasi A, Cozzolino M, Remuzzi G, Ruggenenti P, Kohan DE; ANSWER Study Organization.

Am J Kidney Dis. 2019 Sep;74(3):338-350. doi: 10.1053/j.ajkd.2019.01.029. Epub 2019 Apr 23.

PMID:
31027883
21.

Orphan drugs - Authors' reply.

Luzzatto L, Costa E, Schieppati A, Remuzzi G.

Lancet. 2019 Apr 20;393(10181):1595-1596. doi: 10.1016/S0140-6736(19)30014-5. No abstract available.

PMID:
31007199
22.

CRISPR-Cas9-Mediated Correction of the G189R-PAX2 Mutation in Induced Pluripotent Stem Cells from a Patient with Focal Segmental Glomerulosclerosis.

Trionfini P, Ciampi O, Todeschini M, Ascanelli C, Longaretti L, Perico L, Remuzzi G, Benigni A, Tomasoni S.

CRISPR J. 2019 Apr;2:108-120. doi: 10.1089/crispr.2018.0048.

PMID:
30998089
23.

Why and how did Leonardo happen: the Renaissance context.

Remuzzi G, Ricciardi W.

Lancet. 2019 Apr 6;393(10179):1396-1397. doi: 10.1016/S0140-6736(19)30548-3. Epub 2019 Apr 4. No abstract available.

PMID:
30967202
24.

Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.

Perico N, Ruggenenti P, Perna A, Caroli A, Trillini M, Sironi S, Pisani A, Riccio E, Imbriaco M, Dugo M, Morana G, Granata A, Figuera M, Gaspari F, Carrara F, Rubis N, Villa A, Gamba S, Prandini S, Cortinovis M, Remuzzi A, Remuzzi G; ALADIN 2 Study Group.

PLoS Med. 2019 Apr 5;16(4):e1002777. doi: 10.1371/journal.pmed.1002777. eCollection 2019 Apr.

25.

C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.

Ruggenenti P, Daina E, Gennarini A, Carrara C, Gamba S, Noris M, Rubis N, Peraro F, Gaspari F, Pasini A, Rigotti A, Lerchner RM, Santoro D, Pisani A, Pasi A, Remuzzi G; EAGLE Study Group.

Am J Kidney Dis. 2019 Aug;74(2):224-238. doi: 10.1053/j.ajkd.2018.12.046. Epub 2019 Mar 28.

PMID:
30929851
26.

Hemolytic Uremic Syndrome in an Infant with Primary Hyperoxaluria Type II: An Unreported Clinical Association.

Valoti E, Alberti M, Carrara C, Breno M, Yilmaz Keskin E, Bresin E, Cuccarolo P, Açikgöz Y, Benigni A, Noris M, Remuzzi G, Mele C.

Nephron. 2019;142(3):264-270. doi: 10.1159/000497823. Epub 2019 Mar 19.

PMID:
30889567
27.

An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.

Galbusera M, Noris M, Gastoldi S, Bresin E, Mele C, Breno M, Cuccarolo P, Alberti M, Valoti E, Piras R, Donadelli R, Vivarelli M, Murer L, Pecoraro C, Ferrari E, Perna A, Benigni A, Portalupi V, Remuzzi G.

Am J Kidney Dis. 2019 Jul;74(1):56-72. doi: 10.1053/j.ajkd.2018.11.012. Epub 2019 Mar 7.

PMID:
30851964
28.

Disaster medicine and response: Optimizing life-saving potential.

Sever MS, Remuzzi G, Vanholder R.

Am J Disaster Med. 2018 Fall;13(4):253-264. doi: 10.5055/ajdm.2018.0305. Review.

PMID:
30821339
29.

Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation.

Casiraghi F, Todeschini M, Azzollini N, Cravedi P, Cassis P, Solini S, Fiori S, Rota C, Karachi A, Carrara C, Noris M, Perico N, Remuzzi G.

Transplantation. 2019 Jun;103(6):1121-1130. doi: 10.1097/TP.0000000000002611.

PMID:
30801518
30.

Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.

Ruggenenti P, Trillini M, P Barlovic D, Cortinovis M, Pisani A, Parvanova A, Iliev IP, Ruggiero B, Rota S, Aparicio MC, Perna A, Peraro F, Diadei O, Gaspari F, Carrara F, Stucchi N, Martinetti D, Janez A, Gregoric N, Riccio E, Bossi AC, Trevisan R, Manunta P, Battaglia G, David S, Aucella F, Belviso A, Satta A, Remuzzi G; VALID Study Organization.

Diabetes Obes Metab. 2019 May;21(5):1177-1190. doi: 10.1111/dom.13639. Epub 2019 Feb 22.

PMID:
30793466
31.

Urinary proteome signature of Renal Cysts and Diabetes syndrome in children.

Ricci P, Magalhães P, Krochmal M, Pejchinovski M, Daina E, Caruso MR, Goea L, Belczacka I, Remuzzi G, Umbhauer M, Drube J, Pape L, Mischak H, Decramer S, Schaefer F, Schanstra JP, Cereghini S, Zürbig P.

Sci Rep. 2019 Feb 18;9(1):2225. doi: 10.1038/s41598-019-38713-5.

32.

C3 glomerulopathy - understanding a rare complement-driven renal disease.

Smith RJH, Appel GB, Blom AM, Cook HT, D'Agati VD, Fakhouri F, Fremeaux-Bacchi V, Józsi M, Kavanagh D, Lambris JD, Noris M, Pickering MC, Remuzzi G, de Córdoba SR, Sethi S, Van der Vlag J, Zipfel PF, Nester CM.

Nat Rev Nephrol. 2019 Mar;15(3):129-143. doi: 10.1038/s41581-018-0107-2. Review.

33.

Albuminuria Regression in Diabetes: A Therapeutic Target for Nephro- and Cardio-Protection, in Clinics and Research.

Ruggenenti P, Remuzzi G.

Am J Nephrol. 2019;49(2):143-145. doi: 10.1159/000496275. Epub 2019 Jan 24. No abstract available.

34.

Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.

Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, Eckardt KU, McMurray JJV, Weinrauch LA, Liu J, Claggett B, Lewis EF, Pfeffer MA.

Diabetes Obes Metab. 2019 May;21(5):1199-1208. doi: 10.1111/dom.13642. Epub 2019 Mar 4.

PMID:
30672083
35.

Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome.

Buelli S, Zoja C, Remuzzi G, Morigi M.

Microorganisms. 2019 Jan 10;7(1). pii: E15. doi: 10.3390/microorganisms7010015. Review.

36.

Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA.

Am J Kidney Dis. 2019 Mar;73(3):309-315. doi: 10.1053/j.ajkd.2018.10.006. Epub 2018 Dec 19.

PMID:
30578152
37.

Author Correction: Estimated GFR: time for a critical appraisal.

Porrini E, Ruggenenti P, Luis-Lima S, Carrara F, Jiménez A, de Vries APJ, Torres A, Gaspari F, Remuzzi G.

Nat Rev Nephrol. 2019 Feb;15(2):121. doi: 10.1038/s41581-018-0105-4.

PMID:
30563967
38.

Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients.

Spinelli L, Pisani A, Giugliano G, Trimarco B, Riccio E, Visciano B, Remuzzi G, Ruggenenti P.

Data Brief. 2018 Nov 14;21:2075-2081. doi: 10.1016/j.dib.2018.11.041. eCollection 2018 Dec.

39.

Estimated GFR: time for a critical appraisal.

Porrini E, Ruggenenti P, Luis-Lima S, Carrara F, Jiménez A, de Vries APJ, Torres A, Gaspari F, Remuzzi G.

Nat Rev Nephrol. 2019 Mar;15(3):177-190. doi: 10.1038/s41581-018-0080-9. Review. Erratum in: Nat Rev Nephrol. 2018 Dec 18;:.

PMID:
30518813
40.

Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial.

Spinelli L, Pisani A, Giugliano G, Trimarco B, Riccio E, Visciano B, Remuzzi G, Ruggenenti P; ALADIN-Cardiovascular Study Group.

Int J Cardiol. 2019 Jan 15;275:145-151. doi: 10.1016/j.ijcard.2018.10.063. Epub 2018 Oct 22.

PMID:
30509370
41.

Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.

Donadelli R, Pulieri P, Piras R, Iatropoulos P, Valoti E, Benigni A, Remuzzi G, Noris M.

Front Immunol. 2018 Oct 15;9:2329. doi: 10.3389/fimmu.2018.02329. eCollection 2018.

42.

A comparison of metrics and performance characteristics of different search strategies for article retrieval for a systematic review of the global epidemiology of kidney and urinary diseases.

Bikbov B, Perico N, Remuzzi G; GBD Genitourinary Diseases Expert Group.

BMC Med Res Methodol. 2018 Oct 19;18(1):110. doi: 10.1186/s12874-018-0569-8.

43.

Mesenchymal stromal cells in kidney transplantation.

Casiraghi F, Remuzzi G.

Curr Opin Nephrol Hypertens. 2019 Jan;28(1):40-46. doi: 10.1097/MNH.0000000000000461. Review.

PMID:
30300159
44.

Maternal and environmental risk factors for neonatal AKI and its long-term consequences.

Perico N, Askenazi D, Cortinovis M, Remuzzi G.

Nat Rev Nephrol. 2018 Nov;14(11):688-703. doi: 10.1038/s41581-018-0054-y. Review.

PMID:
30224767
45.

Kidney Disease.

Anand S, Thomas B, Remuzzi G, Riella M, Nahas ME, Naicker S, Dirks J.

In: Prabhakaran D, Anand S, Gaziano TA, Mbanya JC, Wu Y, Nugent R, editors. Cardiovascular, Respiratory, and Related Disorders. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 17. Chapter 13.

46.

Addressing acute kidney injury in critically ill newborn babies.

Perico N, Remuzzi G.

Lancet Child Adolesc Health. 2017 Nov;1(3):161-163. doi: 10.1016/S2352-4642(17)30071-8. Epub 2017 Sep 8. No abstract available.

PMID:
30169159
47.

Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care.

Borrelli S, Chiodini P, De Nicola L, Minutolo R, Provenzano M, Garofalo C, Remuzzi G, Ronco C, Cozzolino MG, Manno C, Costanzo AM, Gualberti G, Conte G.

PLoS One. 2018 Aug 23;13(8):e0202417. doi: 10.1371/journal.pone.0202417. eCollection 2018.

48.

Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA.

Selby NM, Blankestijn PJ, Boor P, Combe C, Eckardt KU, Eikefjord E, Garcia-Fernandez N, Golay X, Gordon I, Grenier N, Hockings PD, Jensen JD, Joles JA, Kalra PA, Krämer BK, Mark PB, Mendichovszky IA, Nikolic O, Odudu A, Ong ACM, Ortiz A, Pruijm M, Remuzzi G, Rørvik J, de Seigneux S, Simms RJ, Slatinska J, Summers P, Taal MW, Thoeny HC, Vallée JP, Wolf M, Caroli A, Sourbron S.

Nephrol Dial Transplant. 2018 Sep 1;33(suppl_2):ii4-ii14. doi: 10.1093/ndt/gfy152.

49.

Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease.

Rota C, Morigi M, Cerullo D, Introna M, Colpani O, Corna D, Capelli C, Rabelink TJ, Leuning DG, Rottoli D, Benigni A, Zoja C, Remuzzi G.

Stem Cell Res Ther. 2018 Aug 14;9(1):220. doi: 10.1186/s13287-018-0960-8.

50.

SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.

Cassis P, Locatelli M, Cerullo D, Corna D, Buelli S, Zanchi C, Villa S, Morigi M, Remuzzi G, Benigni A, Zoja C.

JCI Insight. 2018 Aug 9;3(15). pii: 98720. doi: 10.1172/jci.insight.98720. eCollection 2018 Aug 9.

Supplemental Content

Loading ...
Support Center